EP0000300A1 - Substituted estra-1,3,5(10),6-tetraenes, process for their preparation and use in the synthesis of tritium labelled steroids - Google Patents

Substituted estra-1,3,5(10),6-tetraenes, process for their preparation and use in the synthesis of tritium labelled steroids Download PDF

Info

Publication number
EP0000300A1
EP0000300A1 EP78400016A EP78400016A EP0000300A1 EP 0000300 A1 EP0000300 A1 EP 0000300A1 EP 78400016 A EP78400016 A EP 78400016A EP 78400016 A EP78400016 A EP 78400016A EP 0000300 A1 EP0000300 A1 EP 0000300A1
Authority
EP
European Patent Office
Prior art keywords
methoxy
estra
diol
agent
trien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78400016A
Other languages
German (de)
French (fr)
Other versions
EP0000300B1 (en
Inventor
Alain Jouquey
Jean-Pierre Raynaud
Jean Salmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of EP0000300A1 publication Critical patent/EP0000300A1/en
Application granted granted Critical
Publication of EP0000300B1 publication Critical patent/EP0000300B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Definitions

  • the present invention relates to new steroids from the series of substituted estratetraene, their preparation process and their application to the synthesis of derivatives of the series of astradiols labeled with tritium.
  • the subject of the invention is the steroids of general formula I in which R represents hydrogen or R ', R' being an acyl radical having from 1 to 5 carbon atoms, the benzoyl radical substituted or not, or a tetrahydropyranyl, trityl or trimethylsilyl radical, and R 1 represents an acyl radical having from 1 to 5 carbon atoms, the substituted or unsubstituted benzoyl radical or a tetrahydropyranyl, trityl or trimethylsilyl radical.
  • R and / or R 1 represents. an acyl radical having from 1 to 5 carbon carbon, it may be for example the residue of formic acid, acetic acid, p ropionique, butyric or valeric acids.
  • R and / or R 1 represents a substituted benzoyl radical, it can be substituted for example by a halogen such as chlorine or Bromine, by an alkyl radical having from 1 to 5 carbon atoms, by the trifluoromethoxy radical, or by an alkyloxy radical having from 1 to 5 carbon atoms.
  • a halogen such as chlorine or Bromine
  • the subject of the invention is also a process for preparing the products corresponding to the general formula above.
  • tissues of other classes of steroid hormones glucocorticoids, mineral corticosteroids, androgens or progestogens.
  • Stage B Acetoxy-17 ⁇ dibromo-2, 6 methoxy-11 ⁇ estrene 4 one-3
  • the reaction mixture consisting of 45.2 mg of methoxy-11 ⁇ diacetate estra-1, 3, 5 (10), 6 tetraene diol-3, 17 ⁇ , 10 mg of palladium black and 0.3 cc is cooled with liquid nitrogen. redistilled ethyl acetate, then introduced under vacuum 3.87 cm3 of tritium, measured at 0 ° C. and at normal pressure with a total activity of 10 Ci.
  • reaction mixture is allowed to return to ambient temperature, maintained under stirring for 3 hours, collects the excess of tritium, filters, distills the solvent under reduced pressure and, after removal of the labile tritium, obtains 46 mg of diacetate / 6,7- 3 H / methoxy- 11 ⁇ estra-1, 3, 5 (10) triene diol-3, 17 ⁇ sought for a specific activity of 54.03 Ci / mM.
  • Stage B / 6. 7- 3 H / methoxy-11 ⁇ estra-1, 3, 5 (10) triene diol-3.17 ⁇

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet les stéroïdes nouveaux de formule I: <IMAGE> dans laquelle R représente de l'hydrogène ou R', R' représente un acyle, un benzoyle substitué ou non, un radical tétrahydropyranyle, trityle ou triméthylsilyle et R1 représente un acyle, un benzoyle substitué ou non, un radical tétrahydropyranyle, trityle ou triméthylsilyle, ainsi que leur procédé de préparation et leur application à la préparation de stéroïdes marqués au tritium.The subject of the invention is the new steroids of formula I: <IMAGE> in which R represents hydrogen or R ', R' represents an acyl, a substituted or unsubstituted benzoyl, a tetrahydropyranyl, trityl or trimethylsilyl radical and R1 represents an acyl, a substituted or unsubstituted benzoyl, a tetrahydropyranyl, trityl or trimethylsilyl radical, as well as their process of preparation and their application to the preparation of steroids labeled with tritium.

Description

La présente invention concerne de nouveaux stéroïdes de la série des estratétraènes substitués, leur procédé de préparation at leur application à la synthèse de dérivés de la série des astradiols marqués au tritium.The present invention relates to new steroids from the series of substituted estratetraene, their preparation process and their application to the synthesis of derivatives of the series of astradiols labeled with tritium.

L'invention a pour objet les stéroides de formule générale I

Figure imgb0001
dans laquelle R représente de l'hydrogène ou R', R' étant un radical acyle ayant de 1 à 5 atomes de carbone, le radical benzoyle substitué ou non, ou un radical tétrahydropyranyle, trityle ou triméthylsilyle, et R1 représente un radical acyle ayant de 1 à 5 atomes de carbone, le radical benzoyle substitué ou non ou un radical tétrahydropyranyle, trityle ou triméthylsilyle.The subject of the invention is the steroids of general formula I
Figure imgb0001
 in which R represents hydrogen or R ', R' being an acyl radical having from 1 to 5 carbon atoms, the benzoyl radical substituted or not, or a tetrahydropyranyl, trityl or trimethylsilyl radical, and R 1 represents an acyl radical having from 1 to 5 carbon atoms, the substituted or unsubstituted benzoyl radical or a tetrahydropyranyl, trityl or trimethylsilyl radical.

Lorsque R et/ou R1 représente. un radical acyle ayant de 1 à 5 atomes le carbone, il peut être par exemple le reste d'acides formique, acetique, propionique, butyrique ou valérique.When R and / or R 1 represents. an acyl radical having from 1 to 5 carbon carbon, it may be for example the residue of formic acid, acetic acid, p ropionique, butyric or valeric acids.

Lorsque R et/ou R1 représente un radical benzoyle substitue, il peut être substitué par exemple par un halogène tel que le chlore ou le Brome, par un radical alcoyle ayant de 1 à 5 atomes de carbone , par le radical trifluoro- méthoxy, ou par un radical alcoyloxy ayant de 1 à 5 atomes de carbone.When R and / or R 1 represents a substituted benzoyl radical, it can be substituted for example by a halogen such as chlorine or Bromine, by an alkyl radical having from 1 to 5 carbon atoms, by the trifluoromethoxy radical, or by an alkyloxy radical having from 1 to 5 carbon atoms.

Parmi les produits de formule I, on citera notamment :

  • - l'acétate 17β de méthoxy-11β estra-1, 3, 5(10), 6-tetraen diol-3, 17β
  • - le diacétate de méthoxy-11β estra-1, 3, 5(10), 6-tetraen diol-3, 17β
Among the products of formula I, there may be mentioned in particular:
  • - methoxy-11β acetate 17β estra-1, 3, 5 (10), 6-tetraen diol-3, 17β
  • - methoxy-11β diacetate estra-1, 3, 5 (10), 6-tetraen diol-3, 17β

Les produits de formule générale I sont utiles en tant que produits de départ pour 1 cynthèse de dérivés stéroides substitués marqués au tritium.The products of general formula I are useful as starting materials for the synthesis of substituted steroid derivatives labeled with tritium.

L'invention a également pour objet un procédé de préparation des produits répondant à la formule générale ci-dessus.The subject of the invention is also a process for preparing the products corresponding to the general formula above.

Ce procédé est caractérisé en ce que l'on :

  • - bloque la fonction hydroxyle en position 11β de la 11β -méthoxy nor-testostérone au moyen d'un agent d'estérification ou d'éthérification,
  • - soumet la OR1-17β méthoxy-11β nor-testostérone obtenue, R1 ayant ici et dans ce qui suit les significations précitées, à l'action d'un agent d'halogénation,
  • - fait agir sur le OR1-17β dihalogéno-2, 6 méthoxy-11β estren-4 one-3 résultant un agent de déshalohydrataticn pour obtenir le OR1-17β méthoxy-11β estra-1,3,5(10),6-tetraen ol-3 cherché, dont on bloque, le cas échéant, la fonction hydroxyle en 9 au moyen d'un agent d'estérification ou d'éthérification pour obtenir le OR'3, OR1-17β méthoxy-11β estra-1,3,5(10),6-tetraene, R' ayant les significations précitées .
This process is characterized in that:
  • - blocks the hydroxyl function in position 11β of 11β-methoxy nor-testosterone by means of an esterification or etherification agent,
  • - subjects the OR 1 -17β methoxy-11β nor-testosterone obtained, R 1 having here and in the following the abovementioned meanings, to the action of a halogenating agent,
  • - acts on OR 1 -17β dihalo-2,6,6 methoxy-11β estren-4 one-3 resulting in a dehalohydrataticn agent to obtain OR 1 -17β methoxy-11β estra-1,3,5 (10), 6 -tetraen ol-3 sought, which is blocked, where appropriate, the hydroxyl function at 9 by means of an esterification or etherification agent to obtain OR'3, OR 1 -17β methoxy-11β estra-1 , 3,5 (10), 6-tetraene, R 'having the aforementioned meanings.

Dans les conditions préférentielles de mise en oeuvre, le procédé de l'invention est caractérisé en ce que :

  • -l'agent d'estérification au moyen duquel on bloque la fonction hydroxyle en position 17 ou en position 3 est un acide ou un dérivé fonctionnel d'acide ; ce dérivé fonctionnel peut étre l'anhydride acétique cu le chlorure de benzoyle ;
  • - l'agent d'éthérification au moyen duquel on bloque la fonction hydroxyle en position 17 ou en position 3 est le dihydropyran, le chlorure de trityle ou le chlorure de triméthylsilyle;
  • - l'agent d'halogénation à l'action duquel. on soumet in OR1-17β méthoxy-11β nor-testérone est le brome dans l'acide acétique ;
  • Figure imgb0002
Under the preferential conditions of implementation, the method of the invention is characterized in that:
  • the esterification agent by means of which the hydroxyl function is blocked in position 17 or in position 3 is an acid or a functional acid derivative; this functional derivative can be acetic anhydride or benzoyl chloride;
  • - The etherification agent by means of which the hydroxyl function is blocked in position 17 or in position 3 is dihydropyran, trityl chloride or trimethylsilyl chloride;
  • - the halogenating agent whose action. subject in OR 1 -17β methoxy-11β nor-testone is bromine in acetic acid;
  • Figure imgb0002

Comme déjà indiqué les produits de formule générale I sont les produits de départ pour la synthèse de dérivés stéroides marqués au tritium. Leur application en tant que tels est également un objet de la présente invention et est caractérisée en ce que l'on :

  • - réduit un produit de formule générale I, dans laquelle R et R1l ont les significations précitées, par action d'hydrogène tritié en présence d'un catalyseur,
  • - soumet le /6,7 3H/ OR-3 OR1-17β méthoxy-11β estra-1,3, 5(10)- triene à l'action d'une base forte, ou d'un acide faible en milieu aqueux, ou d'un hydracide, pour obtenir le /6, 7-3H/ méthoxy-11β estra-1, 3, 5(10)-trien diol-3,17β
    que l'on oxyde, selon la réaction d'Openauer, en /6, 7- 3H/ hydrexy-3 méthoxy-11β estra-1, 3, 5(10)-trien one-17, au moyen de cyclohéxanone en présence d'isopronylate d'aluminium;
  • - soumet ce dernier à l'action d'un agent d'éthynylation, en présence de ter -amylate de sodium dans le toluène et obtient le /6, 7 - 3H/ méthoxy-11β éthynyl-17α estradiol.
As already indicated, the products of general formula I are the starting materials for the synthesis of steroid derivatives labeled with tritium. Their application as such is also an object of the present invention and is characterized in that one:
  • - reduces a product of general formula I, in which R and R 11 have the abovementioned meanings, by the action of tritiated hydrogen in the presence of a catalyst,
  • - subjects / 6,7 3H / OR-3 OR 1 -17β methoxy-11β estra-1,3, 5 (10) - triene to the action of a strong base, or of a weak acid in an aqueous medium , or a hydracid, to obtain the / 6,7- 3 H / methoxy-11β estra-1, 3, 5 (10) -trien diol-3,17β
    which is oxidized, according to the Openauer reaction, in / 6, 7- 3 H / 3-hydroxy-methoxy-11β estra-1, 3, 5 (10) -trien one-17, by means of cyclohexanone in the presence aluminum isopronylate;
  • - Subjects the latter to the action of an ethynylating agent, in the presence of sodium teramylate in toluene and obtains / 6, 7 - 3 H / methoxy-11β ethynyl-17α estradiol.

Dans les conditions préférentielles de mise en oeuvre, cette application est caractérisée en ce que :

  • - le catalyseur est l'hydroxyde de palladium,
  • - la base forte est la soude et on opère dans le méthanol,
  • - l'acide aqueux faible est l'acide acétique,
  • - l'hydracide est l'acide chlorhydrique
  • - et l'agent d'éthynylation est l'acétylène.
Under the preferential conditions of implementation, this application is characterized in that:
  • - the catalyst is palladium hydroxide,
  • - the strong base is soda and we operate in methanol,
  • - the weak aqueous acid is acetic acid,
  • - the hydracid is hydrochloric acid
  • - And the ethynylation agent is acetylene.

L'invention a également pour objet, à titre de produits industriels nouveaux et notamment à titre d'intermédiaires nécessaires à l'exécution du procédé d'application des produits de formule générale I, objet de l'invention, les produits suivants :

  • - le /6, 7- 3H/ diacétate de méthoxy-11β estra-1,3, 5(10)-trien diol-3,17β
  • - le /6,7-3H/ méthoxy-11β astra-1, 3, 5(10)-trien diol-3, 17β
  • - le /6,7-3H/ hydroxy-3 méthoxy 11β estra 1, 3, 5(10)-trien one-17.
The subject of the invention is also, as new industrial products and in particular as intermediaries necessary for the execution of the process for applying the products of general formula I, which is the subject of the invention, the following products:
  • - the / 6,7- 3 H / methoxy-11β diacetate estra-1,3, 5 (10) -trien diol-3,17β
  • - le / 6,7- 3 H / methoxy-11β astra-1, 3, 5 (10) -trien diol-3, 17β
  • - le / 6,7- 3 H / hydroxy- 3 methoxy 11β estra 1, 3, 5 (10) -trien one-17.

Parmi ces produits, la /6,7-3H/ méthoxy-11β estra-1, 3, 5(10)-trien diol-3, 17β et le /6,7-3H/ hydroxy-3 méthoxy-11β estra-1, 3, 5(10)-trien one-17, présentent un intérêt particulier.Among these products, the / 6,7- 3 H / methoxy-11β estra-1, 3, 5 (10) -trien diol-3, 17β and the / 6,7- 3 H / hydroxy-3 methoxy-11β estra -1, 3, 5 (10) -trien one-17, are of particular interest.

Ces produits conduisent notamment au /6,7-3H/ méthoxy-11β éthynyl-17α estradiol qui présente une activité spécifique de l'ordre de 53 C1/mM.These products lead in particular to / 6,7- 3 H / methoxy-11β ethynyl-17α estradiol which has a specific activity of the order of 53 C1 / mM.

Ce dernier produit permet l'étude et le dosage du récepteur spécifique d'extrogène présent dans les cellules des tissus ou organes cibles de l'action

Figure imgb0003
tissulaires des autres classes d'hormones stéroidiennes (glucocorticoides, minéralccorticoldes, androgènes ou progestogènes).This last product allows the study and the assay of the specific receptor of exogenous present in the cells of the tissues or organs target of the action.
Figure imgb0003
tissues of other classes of steroid hormones (glucocorticoids, mineral corticosteroids, androgens or progestogens).

Enfin, il permet le dosage du méthoxy-11β éthynyl-17a estradiol dans le plasma ou d'autres liquides biologiques par radioimmuno essai.Finally, it allows the methoxy-11β ethynyl-17a estradiol to be assayed in plasma or other biological liquids by radioimmunoassay.

L'utilisation du /6,7-3H/ méthoxy-11β éthynyl-17a estradiol a été décrite par J. P. RAYNAUD et coll., "Progesterone receptors in normal and Neoplastic Tissues", ed. W.L. Mc GUIRE et Al., Raveh Press, New York, 1977, p.p. 171-191.The use of / 6,7- 3 H / methoxy-11β ethynyl-17a estradiol has been described by JP RAYNAUD et al., "Progesterone receptors in normal and Neoplastic Tissues", ed. WL Mc GUIRE et al., Raveh Press, New York, 1977, pp 171-191.

Le produit de départ du procédé de préparation des produits de formule générale I, le 11β -méthoxy nor-testostérone a été décrit dans le brevet français 2 115 033.The starting product for the process for preparing the products of general formula I, 11β-methoxy nor-testosterone has been described in French patent 2 115 033.

Les exemples suivants illustrent à titre non limitatif la mise en oeuvre de l'invention.The following examples illustrate, without limitation, the implementation of the invention.

Figure imgb0004

  • Point de fusion : + 140°C.
  • Analyse : C21H30O4
  • Calculé : C% 72, 80 H% 8, 73 O% 18, 47.
  • Trouvé : 72,9 8, 5
  • /α/D = + 58°35 (C = 1,2 % dans l'éthanol)
Figure imgb0004
  • Melting point: + 140 ° C.
  • Analysis: C 21 H 30 O 4
  • Calculated: C% 72, 80 H% 8, 73 O% 18, 47.
  • Found: 72.9 8.5
  • / α / D = + 58 ° 35 (C = 1.2% in ethanol)

Stade B : Acétoxy-17β dibromo-2, 6 méthoxy-11β estrène 4 one-3Stage B: Acetoxy-17β dibromo-2, 6 methoxy-11β estrene 4 one-3

On dissout 11,7 7 g du produit obtenu au stade A dans 117 cm3 d'éther anhydre. En maintenant la température à 20°C on ajoute, en 30 minutes, 10, 78 g de brome en solution dans 58, 5 cm3 d'acide acétique. On agite encore 1 5 minutes puis on chasse l'éther sous vide à 30°C. L'extrait sec est repris par 250 ml d'eau. On extrait la phase aqueuse par du chlorure de méthylène, lave la phase organique avec une solution saturée de bicarbonate et ensuite par de l'eau, la sèche sur sulfate de sodium anhydre. Cette solution d'acétoxy-17β dibromo-2, 6 méthoxy-11β estrène-4 one-3 dans le chlorure de méthylène est utilisée telle quelle pour le stade suivant de la synthèse. Stade C : Acétate-17β méthoxy-11β estra-1, 3, 5(10), 6 tetraène diol -3, 17β11.7 7 g of the product obtained in Stage A are dissolved in 117 cm 3 of anhydrous ether. Maintaining the temperature at 20 ° C., 10.78 g of bromine dissolved in 58.5 cm 3 of acetic acid are added over 30 minutes. The mixture is stirred again for 15 minutes and then the ether is removed in vacuo at 30 ° C. The dry extract is taken up in 250 ml of water. The aqueous phase is extracted with methylene chloride, the organic phase is washed with a saturated bicarbonate solution and then with water, dried over anhydrous sodium sulfate. This solution of acetoxy-17β dibromo-2, 6 methoxy-11β estrene-4 one-3 in methylene chloride is used as it is for the next stage of the synthesis. Stage C: Acetate-17β methoxy-11β estra-1, 3, 5 (10), 6 tetraene diol -3, 17β

On mélange 10, 53 g de chlorure de lithium et 117 cm3 de diméthyl formamide. On chauffe sous agitation et sous azote jusqu'à 110-115°C puis on ajoute la solution chlorométhylénique obtenue au stade précédent. On chasse le chlorure de méthylène par distillation puis on laisse 2 heures à 110-115°C sous agitation et sous azote. On refroidit à + 20°C et on verse sur 500 cm3 d'eau et de glace. La gomme obtenue est eextraite par du chlorure de méthylene. On lave la phase organique avec une solution saturée de bicarbonate de sodium puis à l'eau. On sèche sur sulfate de sodium. Aprés évaporation à sec sous vide à + 30°C, on obtient un résidu que l'on purifie par chromatographie sur silice, (éluant benzène 9 acétate d'éthyle 1). Le produit obtenu est lavé au benzène et séché.10.53 g of lithium chloride and 117 cm 3 of dimethyl formamide are mixed. The mixture is heated with stirring and under nitrogen to 110-115 ° C. and then the chloromethylenic solution obtained in the preceding stage is added. The methylene chloride is removed by distillation and then left for 2 hours at 110-115 ° C with stirring and under nitrogen. Cool to + 20 ° C and pour over 500 cm3 of water and ice. The gum obtained is extracted with methylene chloride. The organic phase is washed with a saturated sodium bicarbonate solution and then with water. Dried over sodium sulfate. After evaporation to dryness under vacuum at + 30 ° C., a residue is obtained which is purified by chromatography on silica (eluent benzene 9 ethyl acetate 1). The product obtained is washed with benzene and dried.

On obtient 4, 267 g de produit cherché.

  • F. = + 189°C
  • Les eaux mères reprises par du benzène donnent un 2ème jet de 860 mg de produit fondant à + 189°C.
4.267 g of sought product is obtained.
  • Mp = + 189 ° C
  • The mother liquors taken up in benzene give a second jet of 860 mg of product melting at + 189 ° C.

Stade D : Diacétate du méthoxy-11β estra-1, 3, 5(10), 6 tétraène diol-3, 17βStage D: Methoxy-11β diacetate estra-1, 3, 5 (10), 6 tetraene diol-3, 17β

On dissout 4, 1 g de produit obtenu au stade précédent dans 20 cm3 de pyridine et 10 cm3 d'anhydride acétique. On agite à 20°C pendant 16 heures puis on ajoute 100 cm3 d'eau et de glace. La gomme formée est extraite au chlorure de méthylène. On lave la phase organique à l'acide chlorhydrique N puis par une solution saturée de bicarbonate de sodium et enfin par de l'eau. On sèche sur sulfate de sodium anhydre puis on évapore à sec sous vide. On obtient 4,49 g d'une huile incolore.4.1 g of product obtained in the preceding stage are dissolved in 20 cm 3 of pyridine and 10 cm 3 of acetic anhydride. Stirred at 20 ° C for 16 hours then added 100 cm3 of water and ice. The gum formed is extracted with methylene chloride. The organic phase is washed with N hydrochloric acid and then with a saturated sodium bicarbonate solution and finally with water. It is dried over anhydrous sodium sulfate and then evaporated to dryness under vacuum. 4.49 g of a colorless oil are obtained.

AnalyseAnalysis Spectre UVUV spectrum

Figure imgb0005
Figure imgb0005
Figure imgb0006
Figure imgb0006

Exemple II : /6, 7-3H/ méthoxy-11β éthynyl-17α estradiolExample II: / 6,7- 3 H / methoxy-11β ethynyl-17α estradiol Stade A : Diacétate du /6, 7-3H/méthoxy-11,β estra-1, 3, 5(10) triène diol 3, 17βStage A: Diacetate of / 6,7- 3 H / methoxy-11, β estra-1, 3, 5 (10) triene diol 3, 17β

On refroidit par l'azote liquide le mélange réactionnel constitué par 45, 2 mg de diacétate de méthoxy-11β estra-1, 3, 5(10), 6 tétraène diol-3, 17β, 10 mg de noir palladié et 0, cm3 d'acétate d'éthyle redistillé, puis introduit sous vide 3, 87 cm3 de tritium, mesurés à 0°C et à pression normale d'une activité totale de 10 Ci. Puis on laisse revenir le mélange réactionnel à température ambiante, maintient sous agitation pendant 3 heures, récupère l'excès de tritium, filtre, distille sous pression réduite le solvant et, après élimination du tritium labile, obtient 46 mg de diacétate du /6, 7-3H/ méthoxy-11β estra-1, 3, 5(10) triène diol-3, 17β cherché d'une activité spécifique de 54, 03 Ci/mM.The reaction mixture consisting of 45.2 mg of methoxy-11β diacetate estra-1, 3, 5 (10), 6 tetraene diol-3, 17β, 10 mg of palladium black and 0.3 cc is cooled with liquid nitrogen. redistilled ethyl acetate, then introduced under vacuum 3.87 cm3 of tritium, measured at 0 ° C. and at normal pressure with a total activity of 10 Ci. Then the reaction mixture is allowed to return to ambient temperature, maintained under stirring for 3 hours, collects the excess of tritium, filters, distills the solvent under reduced pressure and, after removal of the labile tritium, obtains 46 mg of diacetate / 6,7- 3 H / methoxy- 11β estra-1, 3, 5 (10) triene diol-3, 17β sought for a specific activity of 54.03 Ci / mM.

Stade B : /6. 7-3H/ méthoxy-11β estra-1, 3, 5(10) triène diol-3,17βStage B: / 6. 7- 3 H / methoxy-11β estra-1, 3, 5 (10) triene diol-3.17β

On agite sous courant d'azote 41 mg du produit obtenu au stade précédent, 4 cm3 de méthanol redistillé, 0, 5 cm3 d'eau et 0, 5 cm3 de lessive de soude 36°Bé. On porte au reflux sous agitation et sous azote pendant 2 heures. Après refroidissement à 20°C on ajoute 0, 5 cm3 d'acide acétique at 1, 5 cm3 d'eau. Le produit cristallise. On glace 1 heure puis on essore et lave à l'eau glacée. On sèche sous vide en présence d'anhydride phosphorique. On obtient 30,6 mg de produit cherché.

  • F. = + 245°C
  • Activité spécifique 52 Ci/mM.
Stirred under a stream of nitrogen 41 mg of the product obtained in the preceding stage, 4 cm3 of redistilled methanol, 0.5 cm3 of water and 0.5 cm3 of sodium hydroxide solution 36 ° Bé. The mixture is brought to reflux with stirring and under nitrogen for 2 hours. After cooling to 20 ° C., 0.5 cm3 of acetic acid and 1.5 cm3 of water are added. The product crystallizes. Ice for 1 hour then drain and wash with ice water. It is dried under vacuum in the presence of phosphoric anhydride. 30.6 mg of sought product is obtained.
  • Mp = + 245 ° C
  • Specific activity 52 Ci / mM.

Stade C : /6,7-3H/ hydroxy-3 méthoxy-11β estra-1,3,5910) triène one-17Stage C: / 6.7- 3 H / 3-hydroxy-methoxy-11β estra-1,3,5910) triene one-17

On amène à 50°C, sous argon, 20, 9 mg du produit obtenu au stade pracédent avec 5 cm3 de toluène et 2 cm3 de cyclohexanone. On distille sous passage d'argon 1 cm3 de toluène. Puis on introduit, en 30 minutes a.l total, 4 fois 1 cm3 d'une solution d'isopropylate d'aluminium dans 50 cm3 de toluène, en distillant au fur et à mesure, de façon à maintenir le volume constant. On laisse encore 15 minutes au reflux sous argon. Ensuite on introduit, en distillant au fur et à mesure, une solution de 1 g de tartrats de sodium et de potassium dans 10 cm3 d'eau. On antraîne les solvants à la vapeur d'eau. On refroidit dans un bain de glace. Le produit cristallise. On agite 30 minutes à 0° avant d'essorer. On lave à l'eau, on sèche sous vide en présence d'anhydride phosphorique à tampérature ambiante. on obtient 18,8 mg de produit brut que l'on utilise tal quel pour le stade suivant de la synthèse.20.9 mg of the product obtained in the preceding stage are brought to 50 ° C. under argon with 5 cm 3 of toluene and 2 cm 3 of cyclohexanone. Distilled under passage of argon 1 cm3 of toluene. Then, in 30 minutes a.l total, 4 times 1 cm 3 of a solution of aluminum isopropylate in 50 cm 3 of toluene are introduced, distilling as and when required, so as to keep the volume constant. Another 15 minutes are allowed to reflux under argon. Next, a solution of 1 g of sodium and potassium tartrates in 10 cm 3 of water is introduced, while distilling off gradually. The solvents are swept away with water vapor. It is cooled in an ice bath. The product crystallizes. Stirred 30 minutes at 0 ° before wringing. Washed with water, dried under vacuum in the presence of phosphoric anhydride at ambient temperature. 18.8 mg of crude product are obtained which is used as is for the next stage of the synthesis.

Stade D : /6,7-3H/ méthoxy-11β éthynyl-17α estradiolStage D: / 6.7-3H / methoxy-11β ethynyl-17α estradiol

Dans 10 cm3 d'une solution de téramylate de sodium à 2, 8 g de Na pour 100 cm3 on fait barboter de l'acétylène pendant 3 heures. Puis on ajoute dans le produit obtenu au stade precédent dissous dans 2, 5 cm3 de téirahydrofurane. On maimient le barbotage d'acétylène pendant 5 heures sous agitation et à températdre ambiante. On remplace le barbotage d'acétylène par de l'argon et on acidifie immédiatement, en refroidissant dans un bain de giace, par 2 cm3 d'acide acétique à 50 % d'eau. On extrait a l'éther

Figure imgb0007
Bubble acetylene for 3 hours in 10 cm 3 of a sodium teramylate solution containing 2.8 g of Na per 100 cm 3. Then added to the product obtained in the previous stage dissolved in 2.5 cm3 of téirahydrofurane. The bubbling of acetylene is controlled for 5 hours with stirring and at room temperature. Replacing the bubbling of acetylene with argon and immediately acidifying, cooling in a giace bath, with 2 cm3 of acetic acid at 50% water. Extracted with ether
Figure imgb0007

Claims (8)

1) Nouveaux stéroïdes de formule générale I :
Figure imgb0008
dans laquelle R représente de l'hydrogène ou R', R' étant un radical acyle ayant de 1 à 5 atomes de carbone, le radical benzoyle substitué ou non, ou un radical tétrahydropyranyle, trityle ou triméthylsilyle, et R1 représente un radical acyle ayant de 1 à 5 atomes de carbone, le radical benzoyle substitué ou non, ou un radical tétrahydropyranyle, trityle ou triméthylsilyle.1) New steroids of general formula I:
Figure imgb0008
 in which R represents hydrogen or R ', R' being an acyl radical having from 1 to 5 carbon atoms, the benzoyl radical substituted or not, or a tetrahydropyranyl, trityl or trimethylsilyl radical, and R 1 represents an acyl radical having from 1 to 5 carbon atoms, the substituted or unsubstituted benzoyl radical, or a tetrahydropyranyl, trityl or trimethylsilyl radical. 2) L'acétate-17β de méthoxy-11β estra-1, 3, 5(10), 6 tétraen diol-3, 17β2) Methoxy-11β acetate-17β estra-1, 3, 5 (10), 6 tetraen diol-3, 17β 3) Le diacétate de méthoxy-11β estra-1, 3, 5(10), 6 tétraen diol-3, 17β3) Methoxy-11β diacetate estra-1, 3, 5 (10), 6 tetraen diol-3, 17β 4) Procédé de préparation des produits tels que définis aux revendications 1, 2 ou 3,caractérisé en ce que l'on : - bloque la fonction hydroxyle en position 17β de la 11β -méthoxy nor-testostérone au moyen d'un agent d'estérification ou d'éthérification, soumet la OR1-17β méthoxy-11β nor-testostérone obtenue, R1 ayant ici et dans ce qui suit les significations précitées, à l'acticn d'un agent d'halogénation, - fait agir sur le OR1-17β dihalogéno-2, 6 méthoxy-11β estren-4one-3 résultant un agent de deshalohydratation pour obtenir le OR1-17β méthoxy- ol-3 cherché, dont on bloque, le cas échéant, la fonction hydroxyle en 3 au moyen, d'un agent d'estérification ou d'éthérification pour obtenir le OR'-3, OR1-17β méthoxy-11β estra 1,3,5(10),6-tétraene, R' ayant les significations précitées 4) Process for preparing the products as defined in claims 1, 2 or 3, characterized in that: - blocks the hydroxyl function in position 17β of 11β-methoxy nor-testosterone by means of an esterification or etherification agent, submits the OR 1 -17β methoxy-11β nor-testosterone obtained, R 1 having here and in what follows the abovementioned meanings, with the action of a halogenating agent, - causes the OR 1 -17β 2-dihalo-6,6 methoxy-11β estren-4one-3 to act on a deshalohydratation agent to obtain the sought-after OR 1 -17β methoxy-ol-3, the blocking of which, if necessary, hydroxyl function in 3 using an esterification or etherification agent to obtain the OR'-3, OR 1 -17β methoxy-11β estra 1,3,5 (10), 6-tetraene, R 'having the above meanings 5) Application des produits tels que définis aux revendications 1, 2 et 3 à la synthèse de composés s-téroides marqués au tritium, caractérisée en ce que l'on : - réduit un produit de formule générale I, dans laquelle R et R1 ont les significations précitées, par action d'hydrogène tritié en présence d'un catalyseur, - soumet le /6,7-3H/ OR-3 OR1-17β méthoxy-11β estra-1,3,5(10)-triene -résultant à l'action d'une base forte, ou d'un acide faible en milieu aqueux, ou d'un hydracide, pour obtenir le /6,7-3H/ méthoxy-11β estra-1, 3, 5(10)-trien diol-3, 17β, que l'on oxyde en /6,7-3H/hydroxy-3 méthoxy-11β estra- 1,3,5(10)-trien one-17 au moyen de cyclohexa- none en présence d'isopropylate d'aluminium, - soumet ce dernier à l'action d'un agent d'éthynylation, en présence de ter-amylate de sodium dans le toluène et obtient le /6,'7-3H/ méthoxy-11β éthynyl-17a estradiol. 5) Application of the products as defined in claims 1, 2 and 3 to the synthesis of s-teroid compounds labeled with tritium, characterized in that: - reduces a product of general formula I, in which R and R 1 have the abovementioned meanings, by the action of tritiated hydrogen in the presence of a catalyst, - subjects / 6,7- 3 H / OR-3 OR 1 -17β methoxy-11β estra-1,3,5 (10) -triene -resulting to the action of a strong base, or an acid weak in aqueous medium, or of a hydracid, to obtain the / 6,7- 3 H / methoxy-11β estra-1, 3, 5 (10) -trien diol-3, 17β, which is oxidized to / 6.7- 3 H / 3-hydroxy-11-methoxy estra-1,3,5 (10) -trien one-17 by means of cyclohexanone in the presence of aluminum isopropylate, - Subjects the latter to the action of an ethynylating agent, in the presence of sodium ter-amylate in toluene and obtains / 6, '7- 3 H / methoxy-11β ethynyl-17a estradiol. 6) Application selon la revendication 5, caractérisée en ce que : - le catalyseur est l'hydroxyde de palladium, - la base forte est la soude et il on opère dans le méthanol, - l'acide aqueux faible est l'acide acétique, - l'hydracide est l'acide chlorhydrique - et l'agent d'éthynylation est l'acétylène. 6) Application according to claim 5, characterized in that: - the catalyst is palladium hydroxide, - the strong base is soda and we operate in methanol, - the weak aqueous acid is acetic acid, - the hydracid is hydrochloric acid - And the ethynylation agent is acetylene. 7) A titre de produits intermédiaires nécessaires à l'exécution du procédé selon la revendication 4: - l'acétate du méthoxy-11β nor-testostérone. - l'acétoxy-17β dibromo-2,6 méthoxy-11β estren-4 one-3. 7) As intermediate products necessary for the execution of the process according to claim 4: - methoxy-11β nor-testosterone acetate. - acetoxy-17β dibromo-2,6 methoxy-11β estren-4 one-3. 8) A titre de produits intermédiaires nécessaires à l'exéoution du procédé selon les revendications 5 et 6 : - le /6,7-3H/ diacétate de méthoxy-11βestra-1,3,5(10)-trien diol-3,17β - le /6,7-3H/ méthoxy-11β astra-1,3,5(10)-trien diol-3,17β - le /6,7-3H/ hydroxy-3 méthoxy-11β estra 1,3,5(10)trien one-17. 8) As intermediate products necessary for carrying out the process according to claims 5 and 6: - le / 6,7- 3 H / methoxy-11βestra-1,3,5 (10) -trien diol-3,17β diacetate - le / 6,7- 3 H / methoxy-11β astra-1,3,5 (10) -trien diol-3,17β - the / 6,7- 3 H / hydroxy-3 methoxy-11β will be 1,3,5 (10) trien one-17.
EP78400016A 1977-06-27 1978-06-12 Substituted estra-1,3,5(10),6-tetraenes, process for their preparation and use in the synthesis of tritium labelled steroids Expired EP0000300B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7719613A FR2401173A1 (en) 1977-06-27 1977-06-27 NEW STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE SYNTHESIS OF STEROIDS TRADEMARKS WITH TRITIUM
FR7719613 1977-06-27

Publications (2)

Publication Number Publication Date
EP0000300A1 true EP0000300A1 (en) 1979-01-10
EP0000300B1 EP0000300B1 (en) 1982-01-06

Family

ID=9192607

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78400016A Expired EP0000300B1 (en) 1977-06-27 1978-06-12 Substituted estra-1,3,5(10),6-tetraenes, process for their preparation and use in the synthesis of tritium labelled steroids

Country Status (7)

Country Link
US (1) US4191697A (en)
EP (1) EP0000300B1 (en)
JP (2) JPS5412362A (en)
CA (1) CA1130277A (en)
DE (1) DE2861501D1 (en)
FR (1) FR2401173A1 (en)
IT (1) IT1105060B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (en) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetic vaccine for the specific induction of cytotoxic T-lymphocytes
DE102017119621A1 (en) 2016-12-01 2018-06-07 Pouya Molana A mayonnaise powder composition and method of making a food product using the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3414508A1 (en) * 1984-04-13 1985-10-24 Schering AG, 1000 Berlin und 4709 Bergkamen MULTIPLE TRITLED STEROID-20.17-SPIROLACTONE AND THEIR USE AS TRACER SUBSTANCES
US4757062A (en) * 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
US6416875B1 (en) 1999-12-15 2002-07-09 Dow Global Technologies Inc. Multi-component articles prepared from hydrogenated block copolymers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020294A (en) * 1950-03-28 1962-02-06 Syntex Sa Production of ring a aromatic steroids
GB1151404A (en) * 1966-06-07 1969-05-07 Roussel Uclaf Novel Gona-1,3,5(10)-Trienes, Processes for their Preparation, and Compositions incorporating them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2115033B1 (en) * 1970-11-24 1974-03-22 Roussel Uclaf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020294A (en) * 1950-03-28 1962-02-06 Syntex Sa Production of ring a aromatic steroids
GB1151404A (en) * 1966-06-07 1969-05-07 Roussel Uclaf Novel Gona-1,3,5(10)-Trienes, Processes for their Preparation, and Compositions incorporating them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 82 (1975) 43644y & YAKUGAKU ZASSHI, 1974 94(11) 1484-8. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431327A1 (en) * 1989-11-10 1991-06-12 Hoechst Aktiengesellschaft Synthetic vaccine for the specific induction of cytotoxic T-lymphocytes
DE102017119621A1 (en) 2016-12-01 2018-06-07 Pouya Molana A mayonnaise powder composition and method of making a food product using the same

Also Published As

Publication number Publication date
FR2401173A1 (en) 1979-03-23
JPS5412362A (en) 1979-01-30
US4191697A (en) 1980-03-04
EP0000300B1 (en) 1982-01-06
DE2861501D1 (en) 1982-02-25
CA1130277A (en) 1982-08-24
IT7850022A0 (en) 1978-06-26
JPS6360035B2 (en) 1988-11-22
IT1105060B (en) 1985-10-28
JPS6220196B2 (en) 1987-05-06
JPS62142196A (en) 1987-06-25
FR2401173B1 (en) 1980-04-04

Similar Documents

Publication Publication Date Title
CH633811A5 (en) 4,9-DIENE 11BETA-SUBSTITUTED STEROID DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
EP0313960B1 (en) Steroids substituted in position 10 by a radical containing a double or triple bond, and process for their preparation
EP0000300B1 (en) Substituted estra-1,3,5(10),6-tetraenes, process for their preparation and use in the synthesis of tritium labelled steroids
EP0024983B1 (en) Amino-14 steroid derivatives and process for their preparation
CH652726A5 (en) 17-OXAZOLINE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN THE PREPARATION OF CORTICOSTEROIDS.
EP0443957B1 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
CA1140110A (en) Process for preparing novel derivatives from androst-4-ene
CA1146531A (en) Process for the preparation of novel 2,2-dimethyl 19-nor steroids
CA1096857A (en) Preparation process of novel 17-spirosultin derivatives and corresponding gamma-hydroxy acids
CA1242696A (en) Intermediates for the preparation of radioactive steroids
EP0275728B1 (en) Steroids containing a keto group at position 23, their preparation, their use in the preparation of compounds of the 20-ketopregnane series, and intermediates of this use
EP0058097B1 (en) Process for the preparation of 17-alpha-hydroxy-17-beta-hydroxyacetyl steroids, and corresponding intermediates obtained
EP0157842A1 (en) NEW PROCESS FOR THE PREPARATION OF 17-g(a)-HYDROXY 19-NOR-PROGESTERONE DERIVATIVES.
CA1096372A (en) No translation available
EP0059146B1 (en) Medicaments derived from 3-hydroxy dodecahydro benz(e) inden-7-on, products derived from 3-hydroxy dodecahydro benz(e) inden-7-on and process for their preparation
EP0087359A2 (en) Nitromethylating reagent, its utilization in the preparation of nitromethylated compounds and some of their derivatives and the compounds obtained
CA1122590A (en) Process for the preparation of steroids and their application to the synthesis of tritium-labeled steroids
CH626378A5 (en)
CA1326235C (en) Steroids useful for preparing compounds of the 20-ketopregnan series
WO1993002095A1 (en) Novel 6-substituted steroids, methods for producing same and pharmaceutical compositions containing said steroids
CH629504A5 (en) 19-Norpregnatetraene derivatives
CH410890A (en) Process for preparing a new reagent useful in particular for obtaining certain lactones of steroid compounds
FR2465748A1 (en) A-NOR-, A-NOR-18-HOMO-STEROIDS AND PROCESS FOR THEIR PREPARATION
BE556145A (en)
FR2477146A1 (en) PROCESS FOR THE PREPARATION OF CALCITROIC ACID AND ITS ESTERS, AND COMPOUNDS THUS OBTAINED

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB NL SE

REF Corresponds to:

Ref document number: 2861501

Country of ref document: DE

Date of ref document: 19820225

EAL Se: european patent in force in sweden

Ref document number: 78400016.8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970516

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970603

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19970609

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970612

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970613

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970630

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970731

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 980612 *ROUSSEL UCLAF

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980611

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980612

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980611

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980612

EUG Se: european patent has lapsed

Ref document number: 78400016.8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT